Avita Medical
RCEL
P/S ratio for Avita Medical (RCEL)
P/S ratio as of June 2024 (TTM): 4.04
According to Avita Medical 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.04067. At the end of 2023 the company had a P/S ratio of 6.99.
P/S ratio history for Avita Medical from 2020 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 6.99 | 45.66% |
| 2022 | 4.80 | -66.1% |
| 2021 | 14.2 | -36.85% |
| 2020 | 22.4 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Organovo ONVO | 98.9 | 2,347.33% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | 17.4 | 330.75% | 🇬🇧 UK |
 Novavax NVAX | 2.60 | -35.70% | 🇺🇸 USA |
 Novocure
NVCR | 3.69 | -8.60% | Jersey |